CORRIGENDA

19th WHO Model List of Essential Medicines (April 2015)

Page 13, lines 21–22

Delete: efavirenz + emtricitabine + tenofovir: Tablet: 600 mg + 200 mg + 300 mg (disoproxil fumarate equivalent to 245 mg tenofovir disoproxil).

Insert: efavirenz + emtricitabine* + tenofovir: Tablet: 600 mg + 200 mg + 300 mg (disoproxil fumarate equivalent to 245 mg tenofovir disoproxil).

* Emtricitabine (FTC) is an acceptable alternative to 3TC, based on knowledge of the pharmacology, the resistance patterns and clinical trials of antiretrovirals.

Page 13, lines 23–24

Delete: emtricitabine + tenofovir: Tablet: 200 mg + 300 mg (disoproxil fumarate equivalent to 245 mg tenofovir disoproxil).

---

1 Please note that the corrections listed here apply to the electronic version of the document found here: http://www.who.int/medicines/news/eml_2015/en/. The revised version of the 19th Model List, incorporating these corrections can be found here: http://www.who.int/medicines/publications/essentialmedicines/en/

Insert: **emtricitabine** + **tenofovir:**

**Tablet:** 200 mg + 300 mg (disopropil fumarate equivalent to 245 mg tenofovir disopropil).

* Emtricitabine (FTC) is an acceptable alternative to 3TC, based on knowledge of the pharmacology, the resistance patterns and clinical trials of antiretrovirals.

Page 14, line 24

Delete: **daclatasvir:**

**Tablet:** 30 mg (as hydrochloride).

Insert: **daclatasvir:**

**Tablet:** 30 mg, 60 mg (as hydrochloride).

Page 20, lines 35–37

Delete: **daunorubicin:**

**Powder for injection:** 50 mg (hydrochloride) in vial.
– acute myelogenous leukemia
– acute promyelocytic leukemia

Insert: **daunorubicin:**

**Powder for injection:** 50 mg (hydrochloride) in vial.
– acute lymphoblastic leukemia
– acute myelogenous leukemia
– acute promyelocytic leukemia

Page 23, lines 29–31

Delete: **trastuzumab:**

**Dose form:**
– early stage HER2 positive breast cancer
– metastatic HER2 positive breast cancer.
Insert: **trastuzumab:**

**Powder for injection:** 60 mg, 150 mg, 440 mg in vial.
- **early stage HER2 positive breast cancer**
- **metastatic HER2 positive breast cancer.**

Page 35, line 23

Delete: **[DATE]**

Insert: 27 February 2015

Page 44, line 11

Delete: **emtricitabine**  >3 months